دورية أكاديمية
Lipocalin-2: a novel potential therapy for GVHD.
| العنوان: | Lipocalin-2: a novel potential therapy for GVHD. |
|---|---|
| المؤلفون: | Markey KA; Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: kmarkey@fredhutch.org. |
| المصدر: | Trends in immunology [Trends Immunol] 2024 Apr; Vol. 45 (4), pp. 231-233. Date of Electronic Publication: 2024 Mar 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 100966032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-4981 (Electronic) Linking ISSN: 14714906 NLM ISO Abbreviation: Trends Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, UK : Elsevier Science Ltd., c2001- |
| مواضيع طبية MeSH: | Graft vs Host Disease*/therapy , Hematopoietic Stem Cell Transplantation*, Animals ; Mice ; Transplantation, Homologous ; Lipocalin-2 |
| مستخلص: | Czech et al. used mouse models of allogeneic hematopoietic stem cell transplantation (allo-HCT) to investigate the role of lipocalin-2 (LCN2) as a newfound regulator of intestinal graft-versus-host disease (GVHD). Administration of recombinant LCN2 protein after disease onset prevented GVHD progression, suggesting that it may play a role in reversing tissue damage that has already begun. Competing Interests: Declaration of interests K.A.M. holds equity and has an advisory role in Postbiotics Plus Research, and consults for Crestone Inc. (Copyright © 2024 Elsevier Ltd. All rights reserved.) |
| المشرفين على المادة: | 0 (Lipocalin-2) |
| تواريخ الأحداث: | Date Created: 20240328 Date Completed: 20240415 Latest Revision: 20240415 |
| رمز التحديث: | 20240415 |
| DOI: | 10.1016/j.it.2024.03.004 |
| PMID: | 38548552 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1471-4981 |
|---|---|
| DOI: | 10.1016/j.it.2024.03.004 |